EUVIMEDObjevte EUVIMED
FallberichtOpen access · CC BY-NC-ND 4.0

Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment

Rina Horikawa, Ryohei Suzuki iD, Yunosuke Yuchi iD, Shuji Satomi, Takahiro Saito, Takahiro Teshima iD, Hirotaka Matsumoto

Journal of Veterinary Internal Medicine · 2024

DOI: 10.1111/jvim.17089 ↗

At a glance

Fallbericht in Journal of Veterinary Internal Medicine, 2024. Written by Rina Horikawa and 6 co-authors. Institution: Laboratory of Veterinary Internal Medicine, School of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science Universi…. Major MEDLINE topics: Hypertension, Pulmonary, Fibrinolytic Agents, Vasodilator Agents. Cited 1 times so far (Crossref); 22 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Japan Society for the Promotion of Science.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

An 8-year-old Leonberger receiving immunosuppressive treatment with clinical signs of acute dyspnea, cyanosis, and difficulty standing was referred to our institution (Day 1). Treatment including oxygen, clopidogrel, and low-molecular-weight heparin was initiated for suspected pulmonary thrombosis. However, exertional dyspnea persisted until Day 10, and increased tricuspid regurgitation velocity, pulmonary vascular resistance, and McConnell's signs also were observed. Thus, beraprost sodium was administered PO on Day 11 to treat suspected pulmonary hypertension. On Day 13, contrast-enhanced computed tomography identified extensive contrast defects in the pulmonary arteries, and IV monteplase was administered on Days 14 and 18, with marked improvement in respiratory status and exertional dyspnea on Day 20. Right ventricular function and McConnell signs also improved, and tricuspid regurgitation velocity and pulmonary vascular resistance decreased. On Day 250, echocardiography indicated further improvement in pulmonary hypertension pathophysiology. The patient was still progressing well with antithrombotic and pulmonary vasodilator treatment 400 days later.

Subjects

MeSH terms (MEDLINE)

Hypertension, PulmonaryFibrinolytic AgentsVasodilator AgentsAnimalsDogsDog DiseasesMaleEpoprostenolThrombosis

Author keywords

beraprost sodiumcontrast‐enhanced computed tomographymonteplasemyocardial strainpulmonary vascular resistancespeckle tracking echocardiography

Substances

Fibrinolytic AgentsVasodilator AgentsberaprostEpoprostenol

Authors and institutions

  • Laboratory of Veterinary Internal Medicine, School of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Tokyo, Japan.
  • Takahashi Animal Hospital, Saitama, Japan.

ORCID profiles: Ryohei Suzuki, Yunosuke Yuchi, Takahiro Teshima

Funding

  • Japan Society for the Promotion of Science

Cite

APA

Horikawa, R., Suzuki, R., Yuchi, Y., Satomi, S., Saito, T., Teshima, T., & Matsumoto, H. (2024). Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment. Journal of Veterinary Internal Medicine. https://doi.org/10.1111/jvim.17089

Vancouver

Horikawa R, Suzuki R, Yuchi Y, Satomi S, Saito T, Teshima T, et al. Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment. Journal of Veterinary Internal Medicine. 2024. doi:10.1111/jvim.17089

BibTeX
@article{Horikawa2024,
  author = {Horikawa, Rina and Suzuki, Ryohei and Yuchi, Yunosuke and Satomi, Shuji and Saito, Takahiro and Teshima, Takahiro and Matsumoto, Hirotaka},
  title = {Pulmonary thrombotic pulmonary hypertension managed using antithrombotic and pulmonary vasodilator treatment},
  journal = {Journal of Veterinary Internal Medicine},
  year = {2024},
  doi = {10.1111/jvim.17089}
}
Start for free →